CON NEWMAN: Open Payments
NPI 1689396723 · SALEM, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$447 in 28 payments from 11 companies in 2025. Trend: 2023 $573 · 2024 $688 · 2025 $447
Food & beverage: $447
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $141 |
| AstraZeneca Pharmaceuticals LP | 5 | $76 |
| Axsome Therapeutics, Inc. | 2 | $56 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $52 |
| Neurocrine BioSciences, Inc. | 2 | $42 |
| Lundbeck LLC | 1 | $19 |
| Merck Sharp & Dohme LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Ardelyx, Inc. | 1 | $15 |
| ABBVIE INC. | 1 | $14 |
Products named: REXULTI, Auvelity, Kerendia, AIRSUPRA, INGREZZA, VYEPTI, GARDASIL 9, JARDIANCE.
Industry payments across UT — which companies pay providers there.
